← All trials
NCT04999332
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Aug 10, 2021
- Last posted
- Aug 10, 2021
- Enrollment
- 58
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cheng Kung UniversityLead sponsor
- China Medical UniversityCollaborator
- Taipei Veteran General hospitalCollaborator
- TTY BiopharmCollaborator
- National Cheng Kung UniversityReponsible party - principal investigator
- Kaohsiung Medical UniversityCollaborator
- Kaohsiung Medical UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- National Cheng Kung UniversityStudy chair
- Taipei Veteran General hospitalOverall official - principal investigator
- National Cheng Kung UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.